American Well

americanwell.com

American Well is a leading telehealth platform in the United States, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. With its belief that digital care delivery will transform healthcare, American Well offers a single, comprehensive platform to support all telehealth needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, American Well powers telehealth solutions for over 130 health systems comprised of 2,000 hospitals and 55 health plan partners with over 7,000 employers, covering over 150 million lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NEURIMMUNE EXPANDS DRUG DISCOVERY COLLABORATION WITH ONO PHARMACEUTICAL IN THE FIELD OF NEURODEGENERATIVE DISEASES

Neurimmune | January 17, 2022

news image

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collabo...

Read More

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

news image

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

news image

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More

GILEAD RESCINDS ORPHAN STATUS REQUEST FOR COVID-19 DRUG

pharma news | March 26, 2020

news image

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market. By asking for orphan status the US pharma sparked concerns that it would charge a premium price for remdesivir, which is being trialled against the disease. Remdesivir has been described by the World Health Organisation as the best hope for a therapy, at least until a vaccine is developed. Gilead decided to rescind the request for orphan statu...

Read More
news image

Business Insights

NEURIMMUNE EXPANDS DRUG DISCOVERY COLLABORATION WITH ONO PHARMACEUTICAL IN THE FIELD OF NEURODEGENERATIVE DISEASES

Neurimmune | January 17, 2022

Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. The collaboration is focused on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases utilizing Neurimmune's proprietary Reverse Translational Medicine™ technology platform, a unique antibody drug creation approach. In November 2017, Ono and Neurimmune signed a first drug discovery collabo...

Read More
news image

Business Insights

BC PLATFORMS PARTNERS WITH EU FUNDED, AI-DRIVEN, CANCER DATA INITIATIVE

BC Platforms | November 25, 2022

BC Platforms a global leader in healthcare data management and analytics announced that it has been chosen as key partner in a European Commission project. Under the EC's Horizon Europe program*, Helsinki University Hospital has been awarded a contract to lead a EURO 7 million consortium project termed ONCOVALUE. BCP will work closely with HUS as a key delivery partner in this major EC project. ONCOVALUE is an Artificial Intelligence-based framework which assesses, in real-tim...

Read More
news image

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More
news image

GILEAD RESCINDS ORPHAN STATUS REQUEST FOR COVID-19 DRUG

pharma news | March 26, 2020

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market. By asking for orphan status the US pharma sparked concerns that it would charge a premium price for remdesivir, which is being trialled against the disease. Remdesivir has been described by the World Health Organisation as the best hope for a therapy, at least until a vaccine is developed. Gilead decided to rescind the request for orphan statu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us